KR20250017221A - 통증의 치료에서 사용을 위한 펩티드 및 방법 - Google Patents

통증의 치료에서 사용을 위한 펩티드 및 방법 Download PDF

Info

Publication number
KR20250017221A
KR20250017221A KR1020247041847A KR20247041847A KR20250017221A KR 20250017221 A KR20250017221 A KR 20250017221A KR 1020247041847 A KR1020247041847 A KR 1020247041847A KR 20247041847 A KR20247041847 A KR 20247041847A KR 20250017221 A KR20250017221 A KR 20250017221A
Authority
KR
South Korea
Prior art keywords
peptide
seq
pain
peptides
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247041847A
Other languages
English (en)
Korean (ko)
Inventor
압델아지즈 모크리치
스테빤 가이야르
Original Assignee
타팔지 세러퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타팔지 세러퓨틱스 filed Critical 타팔지 세러퓨틱스
Publication of KR20250017221A publication Critical patent/KR20250017221A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020247041847A 2022-05-25 2023-05-25 통증의 치료에서 사용을 위한 펩티드 및 방법 Pending KR20250017221A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305773.8 2022-05-25
EP22305773 2022-05-25
PCT/EP2023/064091 WO2023227731A1 (en) 2022-05-25 2023-05-25 Peptides and methods for use in treating pain

Publications (1)

Publication Number Publication Date
KR20250017221A true KR20250017221A (ko) 2025-02-04

Family

ID=81975215

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247041847A Pending KR20250017221A (ko) 2022-05-25 2023-05-25 통증의 치료에서 사용을 위한 펩티드 및 방법

Country Status (12)

Country Link
US (1) US20250213654A1 (cg-RX-API-DMAC7.html)
EP (1) EP4531886A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025519127A (cg-RX-API-DMAC7.html)
KR (1) KR20250017221A (cg-RX-API-DMAC7.html)
CN (1) CN119730868A (cg-RX-API-DMAC7.html)
AR (1) AR129441A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023275937A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253053A1 (cg-RX-API-DMAC7.html)
IL (1) IL317048A (cg-RX-API-DMAC7.html)
MX (1) MX2024014419A (cg-RX-API-DMAC7.html)
TW (1) TW202409064A (cg-RX-API-DMAC7.html)
WO (1) WO2023227731A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026119985A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating wounds and inflammatory diseases
WO2026119983A1 (en) 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
CN103382220A (zh) * 2012-05-03 2013-11-06 北京大学 具有抗感染、抗肿瘤活性的细胞因子fam19a4及其应用
EP2801369A1 (en) 2013-05-06 2014-11-12 Centre National De La Recherche Scientifique TAFA4 compounds and uses thereof for treating pain
CN108699604A (zh) 2016-03-08 2018-10-23 艾克斯-马赛大学 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途

Also Published As

Publication number Publication date
AR129441A1 (es) 2024-08-28
MX2024014419A (es) 2024-12-06
IL317048A (en) 2025-01-01
AU2023275937A1 (en) 2024-12-12
CA3253053A1 (en) 2023-11-30
CN119730868A (zh) 2025-03-28
TW202409064A (zh) 2024-03-01
WO2023227731A1 (en) 2023-11-30
EP4531886A1 (en) 2025-04-09
JP2025519127A (ja) 2025-06-24
US20250213654A1 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
US20250213654A1 (en) Peptides and methods for use in treating pain
Del Bufalo et al. Alpha9Alpha10 nicotinic acetylcholine receptors as target for the treatment of chronic pain
JP7097070B2 (ja) クロライドチャネルの標的発現及びその使用方法
AU2019304569B2 (en) Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
US20250051395A1 (en) Peptides and methods for use in treating pain
US20200024323A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
WO2018152103A1 (en) Myomerger polypeptide, nucleic acid molecules, cells, and related methods
CA3249426A1 (en) CONSTRUCTION OF NUCLEIC ACID FOR THE TREATMENT OF AN INHERITED COAGULATION FACTOR DEFICIENCY AND ITS USE
JP2019070001A (ja) 肝細胞増殖因子及びストローマ細胞由来因子1αを用いた末梢動脈疾患の予防または治療用組成物
EP2919816B1 (en) Combination treatment for amyotrophic lateral sclerosis (als)
OA22072A (en) Peptides and methods for use in treating pain.
OA22140A (en) Peptides and methods for use in treating pain.
US20180030105A1 (en) Therapeutic Compositions and Methods for Disorders Associated with Neuronal Degeneration
JP2024542447A (ja) 脊髄性筋萎縮症の治療に使用する、smn発現を回復させるための有効成分と組み合わせたフィトエクジソン及び/又は20‐ヒドロキシエクジソン誘導体
CN117003854A (zh) 用于预防或治疗骨关节炎的蛋白组合物、mRNA组合物及用途
CN119656310B (zh) 敲低或抑制ant1的试剂在制备预防和/或治疗异位骨化的药物中的应用
WO2013006514A2 (en) Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
Johnson et al. AAV9 gene therapy restores lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-Batten disease
CN108018311A (zh) 通过基因编辑特异靶向肌肉组织mstn治疗恶病质
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物
WO2020022518A1 (ja) 筋萎縮性側索硬化症を含む神経疾患の予防剤及び/又は治療剤
CN121693571A (zh) 用于治疗中枢神经系统蛋白质病的重组腺相关病毒载体
KR20230097330A (ko) Mls-stat3를 포함하는 루푸스 질환의 예방 또는 치료용 조성물
BG67190B1 (bg) Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон
WO2006011491A1 (ja) プラスミドベクター及びトランスジェニック動物並びに医薬のスクリーニング方法及び医薬

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000